Galectin Therapeutics (GALT) Tops Q1 EPS by 2c

Galectin Therapeutics (NASDAQ: GALT) reported Q1 EPS of ($0.19), $0.02 better than the analyst estimate of ($0.21).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• HP shares slide as tech giant forecasts 2027 PC market slump
• AMC Entertainment launches tender offer for $360M in senior notes
• Rubico to shift from semi-annual to quarterly financial reporting